Large Granular Lymphocytic Leukemia : Common Therapies and their Outcomes

Large Granular Lymphocytic Leukemia (LGLL), a rare lymphoproliferative disorder of T cell or Natural Killer cell (NK) origin is characterized by persistent immunodominant clones of CD3+ Cytotoxic T Lymphocyte (CTLs) or CD3NK cells. Dysregulated homeostasis of CTL and NK cells may be due to various pathogenic factors, including the recently identified somatic STAT3 mutations. Occurrence of severe cytopenias necessitates therapy initiation. Due to the rarity of LGL, most of the clinical experience is empiric and based on retrospective analyses. We studied the efficacy of the most frequently used agents in a clinically and molecularly annotated cohort of 152 LGLL patients. Our results demonstrate comparable primary and overall responses to oral cyclosporine A (CsA), Cyclophosphamide (CPM) and Methotrexate (MTX) regimens although the indications spectrum varied due to specific toxicities. Presence of STAT3 mutations did not affect responses or overall survival.

[1]  S. Mustjoki,et al.  STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. , 2012, Blood.

[2]  T. Waldmann,et al.  Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia. , 2012, Blood.

[3]  T. Loughran,et al.  How I treat LGL leukemia. , 2011, Blood.

[4]  J. Bennett,et al.  Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998) , 2010 .

[5]  T. Fest,et al.  Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases , 2010, Haematologica.

[6]  M. Wlodarski,et al.  Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia , 2009, Haematologica.

[7]  R. Albert,et al.  Network model of survival signaling in large granular lymphocyte leukemia , 2008, Proceedings of the National Academy of Sciences.

[8]  J. Maciejewski,et al.  Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. , 2008, Experimental Hematology.

[9]  N. Young,et al.  HLA‐DR4 predicts haematological response to cyclosporine in T‐large granular lymphocyte lymphoproliferative disorders , 2003, British journal of haematology.

[10]  T. Loughran,et al.  Survival signals in leukemic large granular lymphocytes. , 2003, Seminars in hematology.

[11]  A. Berrebi,et al.  Cytokine release by activated T-cells in large granular lymphocytic leukemia associated with autoimmune disorders. , 2002, The hematology journal : the official journal of the European Haematology Association.

[12]  J. Melenhorst,et al.  Large granular lymphocyte leukaemia is characterized by a clonal T‐cell receptor rearrangement in both memory and effector CD8+ lymphocyte populations , 2001, British journal of haematology.

[13]  F. Raffi,et al.  Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. , 2000, The American journal of medicine.

[14]  J. H. Liu,et al.  Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. , 1998, Blood.

[15]  T. Loughran,et al.  Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. , 1994, Blood.

[16]  M. Dhodapkar,et al.  Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? , 1994, Blood.